ABSTRACT
References ...................................................................................................................................... 42
There is a clear need to change drug discovery paradigms fundamentally to meet today’s healthcare
needs. There are epidemics in obesity-related type 2 diabetes and metabolic syndromes as well as
an ever increasing burden from chronic diseases of aging. Drug discovery is becoming increasingly
focused on early treatment with disease modifying drugs. Genomics, proteomics, rapid analog
synthesis, and high throughput screening have yielded many more candidate targets and molecules
for drug discovery and development than ever before, yet it is likely that only a tiny fraction of these
will result in useful drug products. The path of traditional outcomes-based drug discovery and
development within these confines can be long, expensive, and uncertain [1] without early
knowledge that validates the therapeutic concept, endorses the candidate molecule, and facilitates
dose selection.
